East Hanover, NJ – This year, New Jersey Health Foundation (NJHF) granted $135,000 in awards to three Kessler Foundation scientists to support pilot research projects that exhibit promising potential. Foundation researchers will conduct studies that expand research in web-based job interview training for youth on the autism spectrum, upper extremity...
research News
East Hanover, NJ – A research scientist at Kessler Foundation has been awarded a highly competitive Mentored Patient-Oriented Research Career Development Award (K23) from the National Institute on Minority Health and Health Disparities, a part of the National Institutes of Health (NIH). This $704,054, five-year grant will support one of...
East Hanover, NJ – Researchers at Kessler Foundation have published a new clinical protocol examining the combination of aerobic exercise and cognitive rehabilitation to improve learning and memory in individuals with multiple sclerosis (MS) who have mobility disability. The article, “Rationale and methodology for examining the combination of aerobic exercise...
WINNIPEG — Local medical researchers are optimistic they’ve found the key to unlocking a cure for a rare genetic disorder that affects Hutterite babies. Scientists at the University of Manitoba and the Manitoba Institute of Child Health have discovered that a small change in a gene involved in cell growth,...
Melbourne, Australia – The global rise in obesity and diabetes is leading to an epidemic in fatty liver disease affecting 20-30 per cent of the world’s population. Almost a third of people with fatty liver disease go on to develop an advanced form of the disease, known as non-alcoholic steatohepatitis...
Osaka, Japan – Guillain–Barré syndrome (GBS), a rare immune-mediated peripheral neuropathy that can cause permanent disability and even death and be quite severe to manage. In this acute disorder, which typically triggers after a respiratory or gastrointestinal tract infection, the body’s immune system attacks its own peripheral nerves, damaging the...
SEATTLE, WA — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking...
CAMBRIDGE, Mass. — Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, presented the interim safety and efficacy results from its Phase 2 study of KP104 in complement inhibitor-naïve patients with PNH at the 2023 American Society of Hematology (ASH) Annual Meeting held in San...
UNIVERSITY PARK, Pa. — Kissing bugs, or triatomine bugs, are the primary vector for Chagas disease, a major public health concern in Central and South America and even the southern United States. However, there aren’t many good treatment options available, which means that to stop the spread of the potentially life-threatening...
SEOUL, South Korea — More than two-thirds of patients with hepatocellular carcinoma (HCC), who receive surgical interventions, experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University College of Medicine have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after...